Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma

Csepregi, Antal; Ebert, Matthias PA; Röcken, Christoph; Schneider-Stock, Regine; Hoffmann, Juliane; Schulz, Hans-Ulrich; Roessner, Albert; Malfertheiner, Peter

doi:10.1186/1471-2407-10-317

BMC Cancer

Table 1 Results and characteristics of patients with hepatocellular carcinoma (HCC)

From: Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma

Patient	Etiology	Non-tumor tissue					Tumor tissue
		Fibrosis	Methylight		MSP	IRS	Methylight
			Result	PMR			Result	PMR	MSP	IRS
HCC1	alcoholic	6	neg	0.08	neg	4	neg	0.14	neg	0
HCC2	cryptogenic	2	neg	0.04	neg	2	neg	3.73	pos	0
HCC3	HH	3	neg	0.01	pos	2	neg	0.04	pos	0
HCC4	alcoholic	3	neg	0.01	pos	0	neg	0.01	neg	0
HCC5	alcoholic	4	neg	1.39	neg	3	pos	100	neg	0
HCC6	cryptogenic	6	neg	0.19	pos	4	pos	14.64	pos	0
HCC7	cryptogenic	2	neg	0.01	neg	0	neg	0.41	pos	0
HCC8	alcoholic	2	neg	0.01	pos	0	pos	10.43	neg	0
HCC9	cryptogenic	5	neg	0.11	pos	4	pos	39.81	pos	0
HCC10	alcoholic*	4	neg	0.01	neg	2	pos	11.82	pos	4
HCC11	cryptogenic	2	neg	0.05	neg	2	neg	0.01	neg	3
HCC12	alcoholic	4	pos	22.44	neg	2	pos	26.86	pos	0
HCC13	alcoholic	4	neg	0.3	neg	0	pos	31.62	pos	0
HCC14	cryptogenic	1	neg	0.69	neg	3	pos	52.09	pos	0
HCC15	cryptogenic	2	neg	0.01	nd	0	pos	21.43	nd	0
HCC16	alcoholic	6	neg	0.71	pos	2	pos	100	pos	0
HCC17	cryptogenic	2	neg	0.12	nd	4	pos	22.11	nd	0
HCC18	cryptogenic	4	neg	0.15	neg	0	pos	41.06	pos	0
HCC19	alcoholic	6	neg	0.01	neg	0	pos	88.81	pos	0
HCC20	cryptogenic	2	neg	0.01	neg	2	neg	0.03	neg	0
HCC21	cryptogenic	3	neg	0.01	pos	0	pos	24.23	pos	2
HCC22	HBV/HCV	6	neg	1.46	neg	0	neg	1.92	neg	0
HCC23	HCV	1	neg	0.5	neg	0	pos	50.96	pos	0
HCC24	HCV	6	neg	0.86	neg	0	pos	7.91	pos	0
HCC25	HCV	6	neg	0.07	neg	0	neg	1.19	neg	0
HCC26	HCV	3	neg	0.19	pos	0	pos	74.13	pos	0
HCC27	HCV	6	neg	0.82	neg	0	neg	3.59	pos	0
HCC28	HCV	2	neg	2.31	neg	0	pos	11.14	pos	0
HCC29	HCV	6	neg	0.09	neg	0	pos	30.36	pos	0
HCC30	HCV	3	neg	0.19	neg	2	pos	19.78	pos	0
HCC31	HCV	5	neg	0.11	neg	0	pos	14.12	pos	4
HCC32	crpytogenic	2	neg	0.01	nd	nd	pos	88.22	nd	nd
HCC33	cryptogenic	6	neg	0.37	neg	nd	pos	100	neg	nd
HCC34	HCV	6	nd	nd	nd	0	nd	nd	nd	0
HCC35	HCV	6	nd	nd	nd	3	nd	nd	nd	0
HCC36	HCV/alcoholic	6	nd	nd	nd	0	nd	nd	nd	0
HCC37	HCV	5	nd	nd	nd	3	nd	nd	nd	0
HCC38	HCV	6	nd	nd	nd	3	nd	nd	nd	0
HCC39	HCV	5	nd	nd	nd	2	nd	nd	nd	0
HCC40	HCV	5	nd	nd	nd	6	nd	nd	nd	5
HCC41	HCV/alcoholic	3	nd	nd	nd	2	nd	nd	nd	0
HCC42	HCV/alcoholic	6	nd	nd	nd	1	nd	nd	nd	0
HCC43	HCV/alcoholic	na	nd	nd	nd	nd	nd	nd	nd	0
HCC44	HCV	na	nd	nd	nd	nd	nd	nd	nd	0
HCC45	HCV	na	nd	nd	nd	nd	nd	nd	nd	0
HCC46	HCV	na	nd	nd	nd	nd	nd	nd	nd	0
HCC47	HCV	na	nd	nd	nd	nd	nd	nd	nd	0
HCC48	HCV	na	nd	nd	nd	nd	nd	nd	nd	0

HCC, hepatocellular carcinoma; PMR, percentage of methylated reference (%); MSP, methylation specific PCR;
IRS = Immunoreactivity score, nd, not done; na, not available; AFP, alfa fetoprotein; * the tumor was considered as a mixed form of HCC and CCC; HBV, hepatitis B virus; HCV, hepatitis C virus;

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com